



Mictoryl® Pediatric (propiverine hydrochloride) now covered by several public drug plans to treat symptoms associated with overactive bladder

BLAINVILLE, QC, June 7, 2018 – Duchesnay, a specialty pharmaceutical company with a longstanding commitment to women's health, announced today that Mictoryl® Pediatric (propiverine hydrochloride 5 mg) has been added to the public drug plans of Alberta, New Brunswick, Ontario (limited use), Quebec and the Non-Insured Health Benefits (NIHB) Program.

Mictoryl® Pediatric is indicated for the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in pediatric patients, from the age of 5 years, with overactive bladder.

"There continues to be a need for new pediatric-specific therapies for children suffering from overactive bladder in Canada," said Éric Gervais, executive vice-president of Duchesnay. "We are pleased with these recent decisions to include Mictoryl® Pediatric in certain public drug plans, making a treatment with years of research and European market experience more accessible to Canadian families of children with overactive bladder."

About Mictoryl® Pediatric

Mictoryl® Pediatric is available in 5 mg immediate release tablets and is indicated for body weight adjusted dosing in children from the age of 5 years with OAB up to a body weight of 35 kg. In children and adolescents with a body weight over 35 kg, the maximum recommended dose is 30 mg, administered in two daily doses. Mictoryl® Pediatric was developed by Apogepha, a leading German pharmaceutical company, specializing in urology. For more information about this medication, including contraindications, warnings, precautions, adverse reactions and dosing, please consult the [product monograph](#).

About Duchesnay, Inc.

Duchesnay is a specialty pharmaceutical company with a long-standing commitment to women's health. The company focuses on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding. Duchesnay also commercializes a broad portfolio of products in gynecology, urology and gastroenterology to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at various stages of their lives. For more information: duchesnay.com.

-30-

Contact:

Fiona Story
Senior Director, Communications
514 467-5799
fstory@duchesnay.com